Mishe – Oncotelic

About Mishe

This author has yet to write their bio.
Meanwhile lets just say that we are proud Mishe contributed a whooping 1 entries.

Entries by Mishe

News

Conversational Autonomous Robots in GMP Manufacturing

May 8, 2026 /0 Comments/by Mishe

About Oncotelic

Oncotelic is an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Mateon has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503).

About Mishe

Entries by Mishe

Conversational Autonomous Robots in GMP Manufacturing

About Oncotelic

IMPORTANT LINKS

Our Office